Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease

Annals of Oncology

Volumn 13, Issue SUPPL. 1, 2002, Pages 112-116

  Josting, A ^a,b   Engert, A ^a,b   Diehl, V ^a,b   Canellos, G P ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Hodgkin Lymphoma Study Group (GHSG)   (Germany)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; FOLLOW UP; MORTALITY; MULTIMODALITY CANCER THERAPY; REVIEW; SALVAGE THERAPY;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; PROGNOSIS; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0036265402     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/13.S1.112     Document Type: Article

References (27)

1. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
2. Treatment of relapsed Hodgkin's disease: Strategies and prognostic factors
3. Hodgkin's disease. Prognostic factors and treatment startegies
4. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD)
5. Cologne high-dose sequential in patients with relapsed and refractory Hodgkin's disease
6. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
7. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone
8. Late relapse after treatment for clinical stage I and II Hodgkin's disease
9. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols
10. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease
11. Prognostic factors for patients with Hodgkin disease in first relapse
12. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
13. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up
14. Hodgkin's disease: Combination chemotherapy for relapse following radical radiotherapy
15. Second malignancies complicating Hodgkin's disease in remission
16. Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP
17. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse
18. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
19. Outcome of patients with Hodgkin's disease failing after primary MOPP/ABVD
20. Procnostic factors and treatment outcome in primary progressive Hodgkin's lymphoma-a report from the German Hodgkin's Lymphoma Study Group (GHSG)
21. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
22. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT trial (HD-R1)
23. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988
24. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease
25. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission chemotherapy
26. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients
27. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group